Stereological estimates of nuclear star volume and vessels as predictors of chemotherapy response in small cell carcinoma of the lung: A preliminary report

Histopathology

Volumn 35, Issue 3, 1999, Pages 257-266

  Caporrino, C ^a   Saldiva, P H N ^a   Farhat, C A V ^a   Takagaki, T Y ^a   Younes, R N ^b   Capelozzi, V L ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Chemotherapy; Lung neoplasms; Morphometry; Prognostic indices; Pulmonary pathology; Small cell carcinoma

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG SMALL CELL CANCER; MALE; MORPHOMETRICS; PRIORITY JOURNAL; PROGNOSIS; STEREOMETRY; TUMOR BIOPSY;

EID: 0032861613     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1999.00678.x     Document Type: Article

References (42)

1. De Vitta VT, Hellman S, Rosenberg SA. Principles and Practice of Oncology 4th edn. Philadelphia: J. B. Lippincott Co., 1993.
2. Jett JR. Current treatment of unresectable lung cancer. Mayo Clin. Proc. 1993; 68; 603-611.
3. Bunn PA Jr. Current therapy for small cell lung cancer, Semin Oncol. 1996; 23(Suppl. 16):1-4.
4. Wet M. Falkson G, Rapaport BL. Small cell lung cancer analysis of factors influencing the response to treatment and survival. Oncology 1994; 51; 523-534.
5. Sandler AB. Current management of small cell lung cancer. Semin. Oncol. 1997; 24; 463-476.
6. Johnson BE. Management of small-cell lung cancer. Clin. Chest Med. 1993; 14; 173-187.
7. Maurer LH, Pajak TE. Prognostic factors in small cell carcinoma of the lung: a cancer and leukemia group B study. Cancer Trest Rep. 1981; 65; 767-774.
8. Allan SG, Stewart ME, Love S, Cornbleet MA, Smyth JE, Leonard RFC. Prognosis at presentation of small cell carcinoma of the lung. Eur. J. Cancer 1990; 26; 703-705.
9. Crown JPA, Chahinian AP, Jaffrey IS et al. Predictors 5-year survival curability small cell lung cancer. Cancer 1990; 66; 382-386.
10. Rawson NSB, Peto J. An overview of prognostic factors in small cell lung cancer. Br. J. Cancer 1990; 61; 597-604.
11. Gronowitz JS, Bergström R, Nôu E et al. Clinical and serologic marker of stage and prognosis in small cell lung cancer. Cancer 1990; 66; 722-732.
12. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer an analysis of 2580 patient Southwest Oncology Group data base. J. Clin. Oncol. 1990; 8; 1563-1574.
13. Hansen HH. Management of small-cell cancer of the lung, Lancet 1992; 339; 846-849.
14. Albain KS, Crowley JJ. Hutchins L et al. Predictors of survival following relapse or progression of small cell lung cancer. Cancer 1993; 72; 1184-1191.
15. Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without radiation. Cancer Res. 1986; 46; 4189-4194.
16. Osterlind K, Hansen HH, Hansen M, Dombernowsky P. Andersen PK. Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants. J. Clin. Oncol. 1986; 4; 1307-1313.
17. Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small- cell lung cancer patients. Int. J. Cancer. 1987; 39; 146-149.
18. D'Angio GJ. Breslow N. Beckwith JE et al. Treatment of Wilm's tumor. Results of the Third National Wilm's Tumor Study, Cancer 1989; 64; 349-360.
19. Bernardi FC, Capelozzi VL, Takagaki TY, Younes R, Saldiva PHN. Morphometric evaluation of routine histopathological slides is useful in predicting long-term outcome of patients with squamous cell carcinoma of the lung: a preliminary report. Chest 1995; 107; 614-20.
20. Battlehner CN, Saldiva PHN. Carvalho CRR et al. Nuclear/cytoplasmic ratio correlates strongly with survival in non-disseminated neuroendocrine carcinoma of the lung. Histopathology 1993; 22; 31-34.
21. Capelozzi VL, Battlehner CN, Montes GS, Saldiva PHN. fraction of dense-core granules correlates strongly with survival in dissseminated (stage IV) neuroendocrine cell carcinoma of the lung of the well differentiated and small cell subtypes. Pathol. Res. Pract. 1993; 189; 1145-1148.
22. Carvalho HA, Saldiva PHN, Takagaki TY, Capelozzi VL. Stereological estimates of nucleus/cytoplasm ratio and star, on fiberoptic biopsies are of prognostic value to discriminate survival after radiotherapy in advanced squamous cell carcinoma of the lung. Histopathology 1997; 31; 420-429.
23. Cooksey JA, Bitran JD, Dessor RK et al. Small-cell carcinoma of the lung: the prognostic significance of stage on survival. Eur. J. Cancer. 1979; 15; 859-865.
24. Hirsch FR, Matthewsm MJ, Aisner S et al. Histopathologic classification of small cell lung cancer. Cancer 1988; 62; 973-977.
25. Gundersen HJG, Bendtsen TF, Korbo L et al. Some new, simple and efficient sterological methods and their use in pathological research and diagnosis. APMIS 1988; 96; 379-94.
26. SPSS Version 6.1. Chicago: SPSS Inc., 1990.
27. Blomjous CEM, Vos W, Schipper NW et al. The prognostic significance of selective nuclear morphometry in urinary bladder carcinoma. Human Pathol. 1990; 21; 409-411.
28. Lipponen PK, Collan Y, Esklinen MJ, Pesonen E, Sotarauta M. Morphometry in human transitional cell bladder cancer. Eur. Urol. 1990; 17; 155-160.
29. Borland RN, Partin AW, Epstein JI, Brendler CB. The use of nuclear morphometry in predicting recurrence of transitional cell carcinoma. J. Urol. 1993; 149; 272-275.
30. Partin AW, Walsh AC, Epstein JI, Leventhal BG, Gearchart JP. Nuclear morphometry as a predictor of response to therapy In Wilms tumor: a preliminary report. J. Urol. 1990; 144; 952-954.
31. Tosi P, Luzi P, Baak JPA et al. Nuclear morphometry as an important prognostic factor in stage J renal cell carcinoma. Cancer 1986; 58; 2512-2518.
32. Murphy GE, Partin AW, Maygarden SJ, Mobler JL. Nuclear shape analysis for assessment of prognosis in renal cell carcinoma. J. Urol. 1990; 143; 1103-1107.
33. Sabo ONE, Bejar J, Halachmi S, Moskowitz B, Miselevich I. A comparison between histological grade and nuclear morphometry for predicting the clinical outcome of localized renal cell carcinoma. Br. J. Urol. 1996; 78; 33-38.
34. Diamond DA, Berry SJ, Jewell HJ, Eggleston JC, Coffey DS. A new method to assess metastatic potential of human prostate cancer: relative nuclear roundness. J. Urol. 1982; 128; 729-734.
35. Partin AW, Walsh AC, Pitcock RV, Mohler JL, Epstin JL, Coffey DS. A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis. J. Urol. 1898; 142; 1254-1258.
36. Baak JPA, Van Der Ley G. Borderline or malignant ovarian tumour? A case report of decision making with morphometry. J. Clin. Pathol. 1984; 37; 1110-1113.
37. Demopoulos RI. Genega E, Vamvakas E, Carlson E, Mittal K. Papillary carcinoma of the endometrium: morphometric predictors of survival. Int. J. Gyn. Pathol, 1996; 15; 110-118.
38. Baak JPA, Kurver PHJ. de Snoo-Niewlaat AJE. de Graef S, Makkink B, Boon ME. Prognostic indicators in breast cancer - morphometric methods. Histopathology 1982; 6; 327-339.
39. Baak JPA, Van Dop H, Kurver PHJ, Hermans J. The value of morphometry to classic prognosticators in breast cancer. Cancer 1985; 56; 374-382.
40. Lee TK, Horner RD, Silverman JE, Chen YH, Jenny C, Scarantino CW. Morphometric and morphologic evaluations in stage III non-small cell lung cancers. Cancer 1988; 63; 309-316.
41. Cagle PT, Langstone C, Fraire AE, Roggli VL, Greenberg SD. Absence of correlation between nuclear morphometry and survival in stage I non-small cell lung carcinoma. Cancer 1992; 69; 2454-2457.
42. Fraire AE, Roggli VL, Vollmer RT et al. Lung cancer heterogeneity. Prognostic implications. Cancer 1987; 60; 370-175.